Inhibiting corneal transplantation rejection via lymphatic vessel ligation in a novel murine model.
Corneal transplantation
Lymphangiogenesis
Lymphatic vessel ligation
Neovascularisation
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
18
05
2024
accepted:
21
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
The lymphatic system is a crucial contributor to allograft rejection after corneal transplantation. However, no surgical procedures for the central pathway where conjunctival lymphatic vessels converge have been investigated. Therefore, we aimed to establish a murine model of lymphatic vessel ligation and evaluate its inhibitory effect on corneal allograft rejection. A tracer was used to visualise lymphatic vessels, and complications were evaluated. A surgical technique was developed to block the lymphatic vessels. Corneas from C57BL/6 mice were transplanted into BALB/c mice divided into two groups-one with and one without lymphatic vessel ligation, to evaluate their effects on allograft rejection. Graft opacity scores were evaluated for 8 weeks, and immunohistochemistry was used to quantify angiogenesis and lymphangiogenesis. 20% trypan blue used as a tracer showed clear inflow with no complications. The two sutures and cyanoacrylate glue combination demonstrated a blocking effect after 25 days and was thus used for lymphatic ligation. Three and nine out of fourteen eyes showed rejection at 8 weeks post-surgery in the lymphatic vessel ligation and control groups, respectively. Furthermore, neovascularisation and lymphangiogenesis significantly decreased in the lymphatic vessel ligation group. Overall, we present a novel therapeutic strategy for corneal transplantation.
Identifiants
pubmed: 39465339
doi: 10.1038/s41598-024-77160-9
pii: 10.1038/s41598-024-77160-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25692Informations de copyright
© 2024. The Author(s).
Références
Zhou, Y., Wang, T., Tuli, S. S., Steigleman, W. A. & Shah, A. A. Overview of corneal transplantation for the nonophthalmologist. Transpl. Direct. 9, e1434 (2023).
doi: 10.1097/TXD.0000000000001434
Pluzsik, M. T. et al. Changing trends in penetrating keratoplasty indications between 2011 and 2018 - histopathology of 2123 corneal buttons in a single Center in Germany. Curr. Eye Res. 45, 1199–1204 (2020).
doi: 10.1080/02713683.2020.1737716
pubmed: 32114836
Sangwan, V. S., Ramamurthy, B., Shah, U., Garg, P. & Sridhar, M. S. Rao, G. N. Outcome of corneal transplant rejection: A 10-year study. Clin. Exp. Ophthalmol. 33, 623–627 (2005).
doi: 10.1111/j.1442-9071.2005.01107.x
pubmed: 16402956
Yamagami, S., Suzuki, S. & Tsuru, T. Risk factors for graft failure in penetrating keratoplasty. Acta Ophthalmol. Scand. 74, 584–588 (1996).
doi: 10.1111/j.1600-0420.1996.tb00740.x
pubmed: 9017047
Yamagami, S. & Dana, M. R. The critical role of draining lymph nodes in corneal alloimmunization and graft rejection. Invest. Ophthalmol. Vis. Sci. 42, 1293–1298 (2001).
pubmed: 11328742
Hou, Y., Bock, F., Hos, D. & Cursiefen, C. Lymphatic trafficking in the eye: Modulation of lymphatic trafficking to promote corneal transplant survival. Cells. 10, 1661 (2021).
doi: 10.3390/cells10071661
pubmed: 34359831
pmcid: 8306557
Cursiefen, C. et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 5, 2666–2673 (2004).
doi: 10.1167/iovs.03-1380
Lohrberg, M. & Wilting, J. The lymphatic vascular system of the mouse head. Cell. Tissue Res. 366, 667–677 (2016).
doi: 10.1007/s00441-016-2493-8
pubmed: 27599481
pmcid: 5121175
Maloveska, M. et al. Dynamics of Evans blue clearance from cerebrospinal fluid into meningeal lymphatic vessels and deep cervical lymph nodes. Neurol. Res. 40, 372–380 (2018).
doi: 10.1080/01616412.2018.1446282
pubmed: 29619904
Plsková, J., Kuffová, L., Holán, V., Filipec, M. & Forrester, J. V. Evaluation of corneal graft rejection in a mouse model. Br. J. Ophthalmol. 86, 108–113 (2002).
doi: 10.1136/bjo.86.1.108
pubmed: 11801514
pmcid: 1770977
Hegde, S. & Niederkorn, J. Y. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest. Ophthalmol. Vis. Sci. 41, 3341–3347 (2000).
pubmed: 11006223
Wu, Y. et al. Organogenesis and distribution of the ocular lymphatic vessels in the anterior eye. JCI Insight. 5, e135121 (2020).
doi: 10.1172/jci.insight.135121
pubmed: 32641580
pmcid: 7406257
Subileau, M. et al. Eye lymphatic defects induced by bone morphogenetic protein 9 deficiency have no functional consequences on intraocular pressure. Sci. Rep. 10, 16040 (2020).
doi: 10.1038/s41598-020-71877-z
pubmed: 32994463
pmcid: 7524742
Dieterich, L. C., Tacconi, C., Ducoli, L. & Detmar, M. Lymphatic vessels in cancer. Physiol. Rev. 102, 1837–1879 (2022).
doi: 10.1152/physrev.00039.2021
pubmed: 35771983
Petrova, T. V. & Koh, G. Y. Biological functions of lymphatic vessels. Science. 369, eaax4063 (2020).
doi: 10.1126/science.aax4063
pubmed: 32646971
Cursiefen, C. et al. Lymphatic vessels in vascularized human corneas:Iimmunohistochemical investigation using LYVE-1 and podoplanin. Invest. Ophthalmol. Vis. Sci. 43, 2127–2135 (2002).
pubmed: 12091407
Ambati, B. K. et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 443, 993–997 (2006).
doi: 10.1038/nature05249
pubmed: 17051153
pmcid: 2656128
Cursiefen, C. et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113, 1040–1050 (2004).
doi: 10.1172/JCI20465
pubmed: 15057311
pmcid: 379325
Amadio, M., Govoni, S. & Pascale, A. Targeting VEGF in eye neovascularization: What’s new? A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol. Res. 103, 253–269 (2016).
doi: 10.1016/j.phrs.2015.11.027
pubmed: 26678602
Albuquerque, R. J. C. et al. Alternatively spliced VEGF receptor-2 is an essential endogenous inhibitor of lymphatic vessels. Nat. Med. 15, 1023–1030 (2009).
doi: 10.1038/nm.2018
pubmed: 19668192
pmcid: 2882165
Zhang, W., Schönberg, A., Bock, F., Cursiefen, C. & Posttransplant VEGFR1R2 trap eye drops inhibit corneal (lymph)angiogenesis and improve corneal allograft survival in eyes at high risk of rejection. Transl Vis. Sci. Technol. 11, 6 (2022).
doi: 10.1167/tvst.11.5.6
pubmed: 35533080
pmcid: 9100603
Dohlman, T. H. et al. VEGF-trap Aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. Transplantation. 99, 678–686 (2015).
doi: 10.1097/TP.0000000000000512
pubmed: 25606789
Chen, L. et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10, 813–815 (2004).
doi: 10.1038/nm1078
pubmed: 15235599
Chen, G. L. et al. Evaluation of corneal graft survival in mice model. Int. J. Ophthalmol. 6, 578–583 (2013).
pubmed: 24195028
pmcid: 3808900
Ma, D. et al. Conditions affecting enhanced corneal allograft survival by oral immunization. Invest. Ophthalmol. Vis. Sci. 10, 1835–1846 (1998).